Recent Changes in the Treatment Landscape of Acute Myeloid Leukemia
Daniel A. Pollyea, MD, MS, associate professor of medicine and clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses some of the recent advancements in acute myeloid leukemia. Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.
Daniel A. Pollyea, MD, MS, associate professor of medicine and clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses some of the recent advancements in acute myeloid leukemia (AML). Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.
There are many exciting advances that are both here now and on the horizon, Pollyea notes. Some of these advancements include targeted therapies based on protein expression. The key is to target the patient’s immune system so that the patient can kill the tumor themselves, Pollyea explains.
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
